Stereotaxis to acquire Robocath for $20M initial plus up to $25M in earnouts

Stereotaxis, Inc.

Total consideration up to $45M: $20M upfront (cash/stock) plus earnouts of $10M (FDA approval) and $15M (commercial milestones).
Expected close in July 2026, subject to French regulatory clearance and Stereotaxis debt restructuring.
Interim financing of approx. €1.3M provided to Robocath between signing and closing.
Stock consideration capped at 19.9% of outstanding shares pre-closing unless shareholder approval obtained.
Earnout targets based on next-gen interventional device FDA approval and specified product sales thresholds.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Stereotaxis, Inc. entered into Share Sale Agreement with Robocath, the Sellers, and the Manager valued at $20.0 million (effective 2026-04-14).

Action: entry
Agreement: asset purchase
Counterparty: Robocath, the Sellers, and the Manager
Value: $20.0 million
Effective: 2026-04-14

Exact text from the filing

On April 14, 2026, Stereotaxis, Inc. (“Stereotaxis” or the “Company”) entered into a Share Sale Agreement with Robocath, a French société par actions simplifiée , (“Robocath”), the shareholders of Robocath party thereto (the “Sellers”) and an individual serving as manager (the “Manager”) to acquire (the “Acquisition”) shares and other securities collectively representing 100% of the share capital and voting power of Robocath (on a fully-diluted basis) (the “Robocath Securities”) from the Sellers.

View on SEC.gov

Browse all material agreements →

Stereotaxis, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-016685

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.